A reduction of asymmetric dimethylarginine in renal transplant recipients receiving sirolimus-based regimen.
J Med Assoc Thai
; 98 Suppl 1: S9-13, 2015 Jan.
Article
em En
| MEDLINE
| ID: mdl-25764607
ABSTRACT
OBJECTIVE:
Sirolimus may be of benefit in terms ofa reduction of cardiovascular disease in renal transplant recipients. The aim of the present study was to investigate cardiovascular risk markers in renal transplant recipients receiving calcineurin inhibitors (CNI-based regimen), as compared to those receiving sirolimus (SRL-based regimen). MATERIAL ANDMETHOD:
42 patients were recruited (21 patients for each regimen). Plasma concentrations of cardiovascular risk markers, including asymmetric dimethylarginine (ADMA), nitric oxide (NO), homocysteine (Hcy), and total antioxidant status (TAOS) were measured.RESULTS:
Plasma ADMA concentrations were lower in patients with SRL-based regimen, as compared to those with CNI-based regimen (0.52 ± 0.02 and 0.60 ± 0.02 µmol/L, p = 0.027). There were no statistically significant differences seen in NO, Hcy, and TAOS between the two treatments.CONCLUSION:
As compared to CNI-based regimen, cardiovascular risk marker (ADMA) levels are lower in patients with SRL-based regimen.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Arginina
/
Transplante de Rim
/
Sirolimo
/
Imunossupressores
Tipo de estudo:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Med Assoc Thai
Ano de publicação:
2015
Tipo de documento:
Article